Trial reportBMC cardiovascular disorders2026
Efficacy and safety of the paclitaxel drug-coated balloon angioplasty for the treatment of coronary small vessel disease: a prospective, multicenter, randomized clinical trial.
Trial report in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe optimal revascularization strategy for coronary small vessel disease remains controversial due to limited lumen gain and high restenosis risk associated with stent implantation. Drug-coated balloon may offer an alternative by delivering antiproliferative drugs without leaving a permanent implant. This study aimed to evaluate the efficacy and safety of a paclitaxel-coated balloon developed by Hangzhou Revita Medical Technology Co., Ltd. for the treatment of coronary small vessel disease and very small vessel disease.
methodsThis prospective, multicenter, randomized controlled trial enrolled 216 patients with reference vessel diameters between 1.5 and 2.5 mm at eight centers in China. Participants were randomly assigned (1:1) to treatment with a paclitaxel-coated balloon (Drug coated balloon group, n = 109) or a conventional balloon (Uncoated balloon group, n = 107). Patients with RVD < 2.0 mm were defined as the very small vessel disease (VSVD). The primary endpoint was in-lesion late lumen loss at 9 months. Secondary endpoints included minimal lumen diameter, percent diameter stenosis, binary restenosis, and device-oriented major adverse cardiovascular events.
resultsAt 9 months, angiographic follow-up was completed in 176 patients. The drug coated balloon group showed significantly lower in-lesion LLL compared with the uncoated balloon group (0.15 ± 0.34 mm vs. 0.36 ± 0.43 mm, p < 0.001), larger MLD (1.39 ± 0.41 mm vs. 1.13 ± 0.48 mm, p < 0.001), and reduced DS% (28.52 ± 19.11% vs. 42.42 ± 21.72%, p < 0.001). Binary restenosis occurred less frequently in the drug coated balloon group (9.8% vs. 31.0%, p < 0.001). Clinical outcomes were comparable between groups, with no deaths and similar DO-MACE rates (1.8% vs. 2.8%, p = 0.591). The analysis in the very small vessels disease cohort (RVD < 2.0 mm) demonstrated consistent angiographic and clinical benefits.
conclusionsPaclitaxel-coated balloon is safe and effective for the treatment of de novo coronary small vessel lesions, providing superior angiographic outcomes and comparable clinical safety relative to conventional balloon. The efficacy of DCB was consistent in very small vessels (RVD < 2.0 mm).
trial registrationChiCTR2200056430, February 6, 2022 (Retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.